FEG
NVO

Fund Evaluation Group’s Novo Nordisk NVO Stock Holding History

Fund Evaluation Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-74,510
Closed -$1.76M – 67
2018
Q3 		$1.76M Sell
74,510
-6,590
-8% -$161K 0.29% 33
2018
Q2 		$1.87M Hold
81,100
– – 0.3% 31
2018
Q1 		$2M Sell
81,100
-52,780
-39% -$1.39M 0.22% 31
2017
Q4 		$3.59M Buy
+133,880
New +$3.4M 0.39% 16

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fund Evaluation Group's NVO Position: Q4 2018 in Review

Fund Evaluation Group sold out of Novo Nordisk (NVO) in Q4 2018, closing a stake of 74,510 shares — an estimated $1.76M sold.

Fund Evaluation Group first reported a position in NVO in Q4 2017 and held it in 4 quarters. The position peaked at $3.59M in Q4 2017. 550 funds tracked by Wall St. Rank hold NVO as of Q4 2018.

  • Fund Evaluation Group reported no remaining Novo Nordisk position as of Q4 2018 after selling out during the quarter.
  • Fund Evaluation Group sold 74,510 Novo Nordisk shares in Q4 2018, an estimated $1.76M.
  • Fund Evaluation Group first reported a position in Novo Nordisk in Q4 2017 and held it in 4 quarters.
  • Fund Evaluation Group's Novo Nordisk position peaked at $3.59M in Q4 2017.
  • 550 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2018.

Based on Fund Evaluation Group's 13F filing for Q4 2018, filed 12 Feb 2019.